Table I.

Detected gene panel and mutation sites used in the present study.

Gene name	Detected mutation sites
KRAS	Exons 2 and 3
NRAS	Exons 2 and 3
BRAF	Exons 11 and 15
PIK3CA	Exons 9 and 20
KIT	Exons 9, 11, 13, 14 and 17
PDGFRA	Exons 12, 14 and 18
EGFR	Exons 18, 19, 20 and 21
ERBB2	Exon 20
DDR2	Exon 18
ALK	Codon 1196, 1202 and 1206 at exon 23, and codon 1269 at exon 25
RET	Codon 634 at exon 11, codon 918 at exon 16
SMO	Codon 473 at exon 8
TSC1	Exon 15
FLT3	Codon 835 at exon 20, exon 14 and 15
NPM1	Exon 11
DNMT3A	Codon 882 at exon 23, exons 15–22
ABL1	Codons 253–255 at exon 4, codons 299 and 317 at exon 5, and codons 351–359 at exon 6

KRAS, KRAS proto-oncogene, GTPase; NRAS, NRAS proto-oncogene; BRAF, B-Raf proto-oncogene, serine/threonine kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; KIT, KIT proto-oncogene, receptor tyrosine kinase; PDGFRA, platelet derived growth factor receptor alpha; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; DDR2, discoidin domain receptor tyrosine kinase 2; GTPase; ALK, ALK receptor tyrosine kinase; RET, ret proto-oncogene; SMO, smoothened, frizzled class receptor; TSC1, TSC complex subunit 1; FLT3, fms related receptor tyrosine kinase 3; NPM1, nucleophosmin 1; DNMT3A, DNA methyltransferase 3 alpha; ABL1, ABL proto-oncogene 1.